Georgia Retina has a long history of commitment to and participation in clinical trials in order to provide our patients access to new, state-of-the-art preventative, or therapeutic treatments. We partner with the National Eye Institute, some of the nation’s top pharmaceutical companies, and other clinical practices to explore the causes and cures for many retinal conditions.
We take special care to ensure that our study patients experience the best medical care possible.
About Our Research
Georgia Retina continues its dedication to the advancement of ophthalmic science and patient care through the active participation in well-designed, randomized, controlled clinical trials. Participation in clinical research trials helps to bring new and innovative therapies for many blinding conditions into clinical practice and to our patients.
If you are interested in determining your eligibility for a trial, please contact our Clinical Research Coordinator, Leslie Marcus, CCRC at (404) 299-5209.
Wet Age-Related Macular Degeneration
- Allergan 150998-005 CEDAR
- Regeneron R2176-3-AMD-1417 CAPELLA
- Regeneron R910-3-AMD-1517 ONYX
- Roche BP29647 AVENUE
Geographic Atrophy Secondary to Age-Related Macular Degeneration
Retinal Vein Occlusion
Diabetic Macular Edema
Nonprofilerative Diabetic Retinopathy
- AART C-02-60
- Acucela 4429-202 SEATTLE
- ALLERGAN 206207-012
- AREDS2 ForeseeHome
- C-09-067 RACE
- DRCR.net Protocol N
- HORIZON FVF3426g
- MARINA FVF2598g
- Novartis CSPP100A2244
- Ocriplasmin Research to Better Inform Treatment (ORBIT)
- RIDE FVF4168g
- RISE FVF4170g
- SAILOR FVF3689g